The cryptocurrency market has seen impressive rallies over the past months, with Ripple and Cardano gaining significant traction. XRP is currently trading at $2.43 after surging 346.57% in the last 90 days, while ADA is priced at $0.7379, up 92.33% in the same period. Investors speculate whether either of these assets could reach the $10 mark this month, but reality suggests otherwise. While both assets have bullish potential, their current trajectories and market resistances indicate that a $10 valuation remains out of reach in the near term. However, an emerging real-world asset (RWA) cryptocurrency, Rexas Finance (RXS), presents a far greater upside potential. Projections indicated hitting $10 before XRP or ADA even reach $5.
XRP’s Price Outlook: Can It Break $10?
Ripple shows strong price performance. It finds support at $2.03 and bounces 23.21%. Although this points to positive momentum, the token would need an exponential 311% rise to $10.
XRP Daily Price Chart, Feb. 5, 2025, | Source: Tradingview
Though there are encouraging developments regarding Ripple’s SEC case and growing alliances, such a spike in one month seems unworkable. The present resistance levels imply XRP might keep on its slow climb, but investors should lower their hopes of a parabolic rise to double-digit territory.
Cardano’s Struggle: Will ADA Recover?
Cardano has also shown remarkable expansion despite being under great negative pressure. ADA developed a triple top at $1.15 and then dropped 55.55% over three days. This trend points to severe resistance, so the immediate-term $10 price goal is improbable. Cardano’s ecosystem keeps growing as DeFi and smart contracts advance, but given its current price action, an incredible 1,254% increase would be needed to reach $10—an unattainable forecast.
ADA 24-Hours Price Chart, Feb. 5, 2025, | Source: Tradingview
Why Rexas Finance (RXS) Shows Stronger Potential
Rexas Finance (RXS) has shown unprecedented expansion while XRP and ADA fight to lower important resistance levels. Originally costing $0.30 at stage 12 of its presale, RXS has skyrocketed 580%. Sell
Go to Source to See Full Article
Author: Adrian Barkley
